A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7

Puntos clave

• Ivonescimab shows promise as a first-line treatment for metastatic lung cancer, specifically with high PD-L1 expression.
• The study demonstrates a comparative analysis with pembrolizumab, reflecting significant tumor response rates.
• Randomized phase III study highlights crucial insights into immunotherapy effectiveness in metastatic lung cancer.
• Results may indicate new options for treatment in patients with high tumor PD-L1 expression, enhancing care strategies.